Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.

Weiss, G; Green, S; Alberts, D S; Thigpen, J T; Hines, H E; Hanson, K; Pierce, H I; Baker, L H; Goodwin, J W

Weiss, G; Green, S; Alberts, D S; Thigpen, J T; Hines, H E; Hanson, K; Pierce, H I; Baker, L H; Goodwin, J W.

Affiliation

Weiss G; Southwest Oncology Group Operations Office, San Antonio, Texas TB229-6197.

Eur J Cancer ; 27(2): 135-8, 1991.

Article in En | MEDLINE | ID: mdl-1827275

Subject(s)

Antineoplastic Agents/therapeutic use; Organoplatinum Compounds/therapeutic use; Ovarian Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Antineoplastic Agents/adverse effects; Carboplatin/therapeutic use; Cisplatin/therapeutic use; Drug Resistance; Female; Hematologic Diseases/chemically induced; Humans; Middle Aged; Organoplatinum Compounds/adverse effects

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Organoplatinum Compounds / Ovarian Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 1991 Document type: Article Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links